Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Autologous AdE1- Latent Membrane Protein CTLs · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single group study | EXPERIMENTAL | Autologous AdE1- Latent Membrane Protein (LMP) Cytotoxic T Lymphocytes. |
| Name | Type | Description |
|---|---|---|
| Autologous AdE1- Latent Membrane Protein CTLs | BIOLOGICAL | Total dose 20-800 million CTL given in 4 equal doses (5-200 million CTL) given intravenously, at weekly intervals for the first cohort of 10 patients and twice a week for the second cohort of 10 patients. |
Inclusion Criteria: * Informed consent. * EBV-positive lymphoma as determined by in situ hybridization or equivalent (excluding Burkitts Lymphoma). * Age 18 years or older. * ECOG performance status 1, 2 or 3 * Life expectancy of at least 6 months. * Measurable disease: either relapsing, partially ...
Top 20 of 66 competitors
Autologous AdE1-Latent Membrane Protein CTLs is an investigational cell therapy being studied for the treatment of lymphoma. It is currently in Phase 1 clinical development for this indication. The therapy is designed for patients with Epstein-Barr virus (EBV)-positive lymphomas, as it uses EBV-specific T cells to target the disease.
Autologous AdE1-Latent Membrane Protein CTLs is being developed by Atlantic International Corp., a company traded under the ticker symbol ATLN. The therapy is in Phase 1 clinical development for the treatment of lymphoma.
Autologous AdE1-Latent Membrane Protein CTLs is in Phase 1 clinical development. It is an investigational therapy, meaning it has not been approved by regulatory authorities. A Phase 1 clinical trial for this therapy has been completed, with results not yet reported.
Autologous AdE1-Latent Membrane Protein CTLs has been studied in one completed Phase 1 clinical trial, identified as NCT00779337. This trial, titled 'Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas,' enrolled 8 participants in Australia and was not randomized or blinded.
Autologous AdE1-Latent Membrane Protein CTLs is a type of EBV-specific T cell therapy. The clinical trial NCT00779337 describes it as EBV-specific T cells used as therapy for relapsed or refractory EBV-positive lymphomas. This therapy is designed to target EBV-positive lymphoma cells.